BioSpace News Archive

BioCryst Pharmaceuticals, Inc. announced that the company will present at the Bank of America 2020 Healthcare Conference on Thursday, May 14, 2020 at 9:00 a.m. ET and the 2020 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2020 at 3:40 p.m. ET.

Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system diseases, reported financial results for its fiscal 2020 second quarter.

Evelo Biosciences, Inc., Rutgers University, and Robert Wood Johnson University Hospital announced the submission of an Investigational New Drug application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19.

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced its financial results and business highlights for the first quarter ended March 31, 2020.

Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, is pleased to announce U.S. availability of its SARS-CoV-2 quality assessment products – FDA registration enabling immediate usage by U.S. clinical laboratories to evaluate performance, procedures, and workflow of tests that detect SARS-CoV-2 virus, the causative agent of COVID-19 disease.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that its first quarter 2020 financial results will be released on Wednesday, May 13, 2020 before the U.S. financial markets open.

TNX-1810, TNX-1820 and TNX-1830 are Designed to Express Protein Antigens from SARS-CoV-2 That are Different from TNX-1800, Which is Designed to Express Spike Protein

Orchard Therapeutics, a global gene therapy leader, announced a new strategic plan to realize the potential of the hematopoietic stem cell gene therapy approach and reported its financial results for the quarter ended March 31, 2020.

Strengthened Board of Directors and expanded leadership team with appointment of General Counsel

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the BofA Securities Virtual Health Care Conference.